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P R E V I E W SProtein nutrition as therapy for a genetic disorder
of bone?
Bone formation is controlled by a network of transcription factors and signaling molecules. In this issue, Elefteriou et al.
(2006), studying the role of the transcription factor ATF4 in a new mouse model of neurofibromatosis type I skeletal defects,
demonstrate striking effects of changing dietary protein on bone formation abnormalities.Genetic analyses in humans and mice
have uncovered transcription factors
that control osteoblast differentiation
and bone formation through enhancing
(e.g., Runx2 and Osterix) or diminishing
(e.g., Twist) the expression of target
genes (Karsenty and Wagner, 2002).
Other genetic mutations pinpoint previ-
ously unrecognized pathways of control
of bone formation. For example, activa-
tion of Lrp5 (a component of the Wnt sig-
naling complex) results in a rare high
bone-mass syndrome; inactivation of
Lrp5 is accompanied by severe osteo-
porosis. Genetic inactivation of SOST
results in another rare ‘‘big-bone’’ syn-
drome—SOSTencodes theprotein prod-
uct sclerostin, which is localized in bone
to the osteocyte and operates as a
powerful inhibitor of bone formation.
Novel aspects of transcriptional con-
trol of bone development are reported
in this issue of Cell Metabolism by Elef-
teriou et al. (2006), showing quite re-
markably that the increased bone-mass
phenotype resulting from neurofibromin
(Nf1) deficiency can be rescued through
nutritional restriction of protein intake. In
addition, the opposite skeletal pheno-
type, Atf4 deficiency, which is analogous
to Coffin-Lowry syndrome, can be res-
cued by high protein feeding.
These authors had shown previously
that mice null for either the transcription
factor Atf4 or its essential activatingCELL METABOLISM : DECEMBER 2006kinase, Rsk2, exhibited greatly impaired
bone formation, with reduced numbers
and thickness of bone trabeculae (Yang
et al., 2004). The defect in bone formation
continued postnatally, after having be-
come obvious relatively late in fetal
development. Type I collagen protein
synthesis was decreased almost 10-fold
in Atf42/2 osteoblasts, even though ex-
pression of a(I) collagen was unchanged.
Notably, the defect in collagen produc-
tion was corrected in vitro by addition of
nonessential amino acids, indicating
that the failed collagen production re-
sulted from a posttranscriptional effect.
This revealed in osteoblasts a regulatory
role of ATF4 in amino acid transport that
had been recognized in other cell types
(Harding et al., 2003).
In the present work (Elefteriou et al.,
2006), the authors used a mouse model
to investigate the skeletal phenotype
seen in patients with neurofibromatosis
type 1, which results from deficiency
of the Nf1 protein product, a tumor-
suppressor protein. Skeletal abnormali-
ties in these patients include bowing of
the long bones and pseudoarthroses
and increase with age (Ruggieri et al.,
1999). Since ablation of Nf1 in mice
is embryonic lethal and since Nf1 was
found to be amply expressed in osteo-
blasts, the authors chose to prepare
mice in which Nf1 was ablated specifi-
cally in osteoblasts.In the Nf1ob
2/2 mice, bone volume in-
creased progressively starting soon after
birth, with quantitative histomorphome-
try showing increases in osteoblast sur-
face and number, osteoid amount, and
bone formation rate (Figure 1). Addition-
ally, bone resorption was increased,
with increased osteoclasts in bone and
excretion of a marker of bone resorption.
Importantly, the enhanced osteoclast
formation was not cell autonomous but
required coculture of Nf1-deficient oste-
oblasts with wild-type hematopoietic
cells. Thus, the phenotype appeared to
be the opposite of that accompanying
Atf4 or Rsk2 deficiency.
The critical clue, however, came
frommolecular studies in bone and oste-
oblasts: production of type I collagen
protein was increased despite normal
collagen mRNA in osteoblasts and bone
of Nf1ob
2/2 mice. Although the amount of
ATF4 was not increased in the bones
of mutant mice, its activation by its cru-
cial kinase, RSK2, was enhanced, lead-
ing to the conclusion that NF1 acts in
the osteoblast to limit phosphorylation
of ATF4 by RSK2 and, in so doing, limits
expression of osteocalcin as well as the
transport of amino acids necessary for
the synthesis of the most abundant pro-
tein in bone, type I collagen. Confirma-
tion of the mechanism came by over-
expressing Atf4 in osteoblasts and
generating mice that recapitulated the419
P R E V I E W SFigure 1. Increased bone formation, bone resorption, and osteoid amount are associated with Nf1 deficiency
and/or Atf4 excess
Opposite bone effects are associated with deficiency of either Atf4 or Rsk2. Resorption of mineralized bone
(gray) by osteoclasts and osteoid synthesis (yellow) by osteoblasts are shown. Protein nutrition affects only
the bone formation phenotype.Nf1ob
2/2 skeletal phenotype, as well as
showing that crossing Nf1ob
2/2 mice
with Atf4+/2 mice partially rescued the
phenotype.
The enhanced expression of Rankl in
Nf1ob
2/2 mice was sufficient to explain
the increased osteoclast formation seen
in Nf1 deficiency. As shown previously
by these authors (Elefteriou et al., 2005),
the increased RANKL production re-
quires a different phosphorylation event,
in which ATF4 is phosphorylated at ser-
ine 254 by protein kinase A (PKA). Not
surprisingly, the osteoclast phenotypes
remained unaffected by the manipula-
tions of protein nutrition that were so
dramatically effective on the formation
phenotypes (Figure 1). The finding of
increased PKA activity inNf1ob
2/2 osteo-
blasts is in itself worthy of further ex-
ploration, particularly to establish (as
seems likely) that the lack of NF1 in cells
of the osteoblast lineage is associated
with enhanced cAMP accumulation,
which would explain the increased PKA
activity. NF1 has been shown to antago-420nize the accumulation of cAMP and the
expression of cyclin D1 in Schwann cells
(Kim et al., 2001), but it is interesting to
note that it has the reverse effect in Dro-
sophila, enhancing activity of adenylate
cyclase (Guo et al., 1997). It would be
useful to examine the actions of other
cAMP agonists (e.g., parathyroid hor-
mone, prostaglandin E, and b-agonists)
on Nf1ob
2/2 osteoblasts and their
precursors.
In translating these findings to
human medicine, could the progress of
skeletal manifestations of Coffin-Lowry
syndrome (Rsk2 deficiency) or neurofi-
bromatosis be modified by dietary pro-
tein supplementation or restriction, re-
spectively? Any contribution that could
be made by dietary manipulations to
management of a genetic disorder would
indeed be of remarkable novelty and in-
terest. Also, do these therapeutic effects
of protein diet have broader implica-
tions? It is worth revisiting what is known
of effects of dietary protein on the skele-
ton in a less dramatic setting. High pro-tein intake was associated with reduced
age-related bone loss in a study of el-
derly men and women (Hannan et al.,
2000) and resulted in less bone loss in
a study of subjects with recent hip frac-
ture (Schurch et al., 1998). It would also
be of interest to investigate the Atf4,
Rsk2, and Nf1 genes among candidate
contributors to the multigene disorder
osteoporosis.
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